Companies House 14576167 2025-01-31 2025-01-31 2024-02-01 false iso4217:GBP xbrli:pure 14576167 2023-01-06 2024-01-31 14576167 2025-01-31 14576167 2024-02-01 2025-01-31 14576167 2024-01-31 14576167 curr:PoundSterling 2024-02-01 2025-01-31 14576167 uk-bus:CompanyLimitedByGuarantee 2024-02-01 2025-01-31 14576167 uk-bus:FRS102 2024-02-01 2025-01-31 14576167 uk-bus:AuditExempt-NoAccountantsReport 2024-02-01 2025-01-31 14576167 uk-bus:FullAccounts 2024-02-01 2025-01-31 14576167 uk-bus:RegisteredOffice 2024-02-01 2025-01-31 14576167 uk-bus:Director1 2024-02-01 2025-01-31 14576167 uk-bus:Director2 2024-02-01 2025-01-31 14576167 uk-bus:Director3 2024-02-01 2025-01-31 14576167 uk-bus:Director4 2024-02-01 2025-01-31 14576167 uk-bus:Director5 2024-02-01 2025-01-31 14576167 uk-bus:Director6 2024-02-01 2025-01-31 14576167 uk-bus:Director7 2024-02-01 2025-01-31 14576167 uk-bus:Director8 2024-02-01 2025-01-31 14576167 uk-bus:Director9 2024-02-01 2025-01-31 14576167 uk-bus:Director10 2024-02-01 2025-01-31 14576167 uk-bus:Director11 2024-02-01 2025-01-31 14576167 uk-bus:Director12 2024-02-01 2025-01-31 14576167 uk-bus:Director13 2024-02-01 2025-01-31 14576167 uk-bus:Director14 2024-02-01 2025-01-31 14576167 uk-bus:Director15 2024-02-01 2025-01-31 14576167 uk-bus:Director16 2024-02-01 2025-01-31 14576167 uk-bus:Director17 2024-02-01 2025-01-31 14576167 uk-bus:Director18 2024-02-01 2025-01-31 14576167 uk-bus:Director19 2024-02-01 2025-01-31 14576167 uk-bus:Director20 2024-02-01 2025-01-31 14576167 uk-bus:Director21 2024-02-01 2025-01-31 14576167 uk-bus:CompanySecretary1 2024-02-01 2025-01-31 14576167 core:AfterOneYear 2025-01-31 14576167 core:AfterOneYear 2024-01-31 14576167 core:WithinOneYear 2025-01-31 14576167 core:WithinOneYear 2024-01-31 14576167 core:WithinOneYear 2024-02-01 2025-01-31 14576167 core:AfterOneYear 2025-01-31 14576167 core:AfterOneYear 2024-01-31 14576167 core:AfterOneYear 2024-02-01 2025-01-31 14576167 core:ShareCapital 2025-01-31 14576167 core:ShareCapital 2024-01-31 14576167 core:SharePremium 2025-01-31 14576167 core:SharePremium 2024-01-31 14576167 core:OtherReservesSubtotal 2025-01-31 14576167 core:OtherReservesSubtotal 2024-01-31 14576167 core:RevaluationReserve 2025-01-31 14576167 core:RevaluationReserve 2024-01-31 14576167 core:RetainedEarningsAccumulatedLosses 2025-01-31 14576167 core:RetainedEarningsAccumulatedLosses 2024-01-31 14576167 1 2024-02-01 2025-01-31 14576167 2 2024-02-01 2025-01-31 14576167 3 2024-02-01 2025-01-31 14576167 core:LandBuildings 2024-02-01 2025-01-31 14576167 core:LandBuildings 2025-01-31 14576167 core:LandBuildings 2023-01-06 2024-01-31 14576167 core:LandBuildings 2024-01-31 14576167 core:PlantMachinery 2024-02-01 2025-01-31 14576167 core:PlantMachinery 2025-01-31 14576167 core:PlantMachinery 2023-01-06 2024-01-31 14576167 core:PlantMachinery 2024-01-31 14576167 core:FurnitureFittingsToolsEquipment 2024-02-01 2025-01-31 14576167 core:FurnitureFittingsToolsEquipment 2025-01-31 14576167 core:FurnitureFittingsToolsEquipment 2023-01-06 2024-01-31 14576167 core:FurnitureFittingsToolsEquipment 2024-01-31 14576167 core:OfficeEquipment 2024-02-01 2025-01-31 14576167 core:OfficeEquipment 2025-01-31 14576167 core:OfficeEquipment 2023-01-06 2024-01-31 14576167 core:OfficeEquipment 2024-01-31 14576167 core:Vehicles 2024-02-01 2025-01-31 14576167 core:Vehicles 2025-01-31 14576167 core:Vehicles 2023-01-06 2024-01-31 14576167 core:Vehicles 2024-01-31 14576167 core:NetGoodwill 2024-02-01 2025-01-31 14576167 core:NetGoodwill 2025-01-31 14576167 core:NetGoodwill 2023-01-06 2024-01-31 14576167 core:NetGoodwill 2024-01-31 14576167 core:IntangibleAssetsOtherThanGoodwill 2024-02-01 2025-01-31 14576167 core:IntangibleAssetsOtherThanGoodwill 2025-01-31 14576167 core:IntangibleAssetsOtherThanGoodwill 2023-01-06 2024-01-31 14576167 core:IntangibleAssetsOtherThanGoodwill 2024-01-31

# THERAPEUTIC PRODUCTIONS CIC

## Company limited by guarantee

## Company Registration Number:
14576167 (England and Wales)

## Unaudited statutory accounts for the year ended 31 January 2025

## Period of accounts

## Start date: 1 February 2024

## End date: 31 January 2025

# THERAPEUTIC PRODUCTIONS CIC

## Contents of the Financial Statements

for the Period Ended 31 January 2025

Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# THERAPEUTIC PRODUCTIONS CIC

## Balance sheet

As at 31 January 2025

| Notes | 2025 | 13 months to 31 January 2024
--- | --- | --- | ---
|  | £ | £
Fixed assets
Intangible assets: |  | 0 | 0
Tangible assets: |  | 0 | 0
Investments: |  | 0 | 0
Total fixed assets: |  | 0 | 0
Current assets
Stocks: |  | 0 | 0
Debtors: | 3 | 13,000 | 0
Cash at bank and in hand: |  | 100 | 30,000
Investments: |  | 0 | 0
Total current assets: |  | 13,100 | 30,000
Prepayments and accrued income: |  | 0 | 0
Creditors: amounts falling due within one year: |  | 0 | 0
Net current assets (liabilities): |  | 13,100 | 30,000
Total assets less current liabilities: |  | 13,100 | 30,000
Creditors: amounts falling due after more than one year: |  | 0 | 0
Provision for liabilities: |  | 0 | 0
Accruals and deferred income: |  | ( 60,451 ) | 0
Total net assets (liabilities): |  | (47,351) | 30,000
Members' funds
Profit and loss account: |  | (47,351) | 30,000
Total members' funds: |  | ( 47,351) | 30,000

The notes form part of these financial statements

# THERAPEUTIC PRODUCTIONS CIC

## Balance sheet statements

For the year ending 31 January 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 3 July 2025
and signed on behalf of the board by:

Name: Jerome Sewell
Status: Director

The notes form part of these financial statements

# THERAPEUTIC PRODUCTIONS CIC

## Notes to the Financial Statements

for the Period Ended 31 January 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

# THERAPEUTIC PRODUCTIONS CIC

## Notes to the Financial Statements

for the Period Ended 31 January 2025

- ## 2. Employees

  | 2025 | 13 months to 31 January 2024
  --- | --- | ---
  Average number of employees during the period | 3 | 3

# THERAPEUTIC PRODUCTIONS CIC

## Notes to the Financial Statements

for the Period Ended 31 January 2025

## 3. Debtors

| 2025 | 13 months to 31 January 2024
--- | --- | ---
| £ | £
Trade debtors | 13,000 | 0
Prepayments and accrued income | 0 | 0
Other debtors | 0 | 0
Total | 13,000 | 0
Debtors due after more than one year: | 0 | 0

# COMMUNITY INTEREST ANNUAL REPORT

### THERAPEUTIC PRODUCTIONS CIC

### Company Number: 14576167 (England and Wales)

### Year Ending: 31 January 2025

Company activities and impact

We have provided skills based training and intensive peer support for mental health patients in hospital. This has included training people as illustrators and artists and advice on careers.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
3 July 2025

And signed on behalf of the board by:
Name: Jerome Sewell
Status: Director